This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
Does surgical smoke spread bladder cancer during RARC? New research finds no cancer cells or DNA present. Learn more about ...
Stocktwits on MSN
IBRX stock rises premarket as founder flags early Anktiva immune data — Macau nod fuels bull case
Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study. ・Anktiva was also added to Macau’s drug list and included in updated NCCN guidelines for ...
Shenouda With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
When someone is diagnosed with colorectal cancer—which includes both colon and rectal cancers—many people immediately think "surgery." And it's true that surgery plays a central role in treatment for ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...
Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...
In this episode of From Bench to Bedside and Beyond, Dr. Yaw Nyame and patient Dave Lucas discuss the robotic surgical approach that enabled Lucas to carry on with his vacation plans and the value of ...
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...
Zacks Investment Research on MSN
JNJ's bladder cancer therapy meets key goal in early-stage study
Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results